Characterization of an FTLD-PDB family with the coexistence of SQSTM1 mutation and hexanucleotide (G4C2) repeat expansion in C9orf72 gene
暂无分享,去创建一个
C. Broeckhoven | R. Guerreiro | I. Santana | M. R. Almeida | O. Rebelo | L. Letra | J. Zee | A. Santos | P. Pires | Paula Pires
[1] C. Broeckhoven,et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter , 2015, Molecular Psychiatry.
[2] F. Ginanneschi,et al. Double trouble? Progranulin mutation and C9ORF72 repeat expansion in a case of primary non-fluent aphasia , 2014, Journal of the Neurological Sciences.
[3] F. Jessen,et al. Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration , 2014, Acta Neuropathologica.
[4] Colin J. Mahoney,et al. A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia , 2014, Neuropathology and applied neurobiology.
[5] J. Hardy,et al. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. , 2013, JAMA neurology.
[6] Kevin F. Bieniek,et al. C9ORF72 repeat expansions in cases with previously identified pathogenic mutations , 2013, Neurology.
[7] M. Filippi,et al. Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation , 2013, Biological Psychiatry.
[8] J. Belleroche,et al. Sequestosome-1 (SQSTM1) sequence variants in ALS cases in the UK: prevalence and coexistence of SQSTM1 mutations in ALS kindred with PDB , 2013, European Journal of Human Genetics.
[9] V. Meininger,et al. Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology , 2013, Acta Neuropathologica.
[10] C. Shaw,et al. Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant , 2013, Acta Neuropathologica.
[11] F. Jessen,et al. A Pan-European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats , 2012, Human mutation.
[12] P. S. St George-Hyslop,et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis , 2012, Neurology.
[13] P. Pietrini,et al. Screening for C9ORF72 repeat expansion in FTLD , 2012, Neurobiology of Aging.
[14] Jacques P. Brown,et al. Epidemiogenetic study of French families with Paget's disease of bone. , 2012, Joint, bone, spine : revue du rhumatisme.
[15] Janel O. Johnson,et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study , 2012, The Lancet Neurology.
[16] D. Neary,et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. , 2012, Brain : a journal of neurology.
[17] David T. Jones,et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72 , 2012, Brain : a journal of neurology.
[18] S. Pereson,et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study , 2012, The Lancet Neurology.
[19] T. Hortobágyi,et al. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS , 2011, Acta Neuropathologica.
[20] T. Ferman,et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72 , 2011, Acta Neuropathologica.
[21] S. Ajroud‐Driss,et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. , 2011, Archives of neurology.
[22] David Heckerman,et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.
[23] D. Geschwind,et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.
[24] Nick C Fox,et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.
[25] M. Brandi,et al. Characterization of a Non‐UBA Domain Missense Mutation of Sequestosome 1 (SQSTM1) in Paget's Disease of Bone , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] Xun Hu,et al. TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis , 2008, Science.
[27] G. Bjørkøy,et al. p62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy* , 2007, Journal of Biological Chemistry.
[28] S. Ralston,et al. Loss of Ubiquitin Binding Is a Unifying Mechanism by Which Mutations of SQSTM1 Cause Paget’s Disease of Bone , 2006, Calcified Tissue International.
[29] G. Bjørkøy,et al. p62/SQSTM1: A Missing Link between Protein Aggregates and the Autophagy Machinery , 2006, Autophagy.
[30] N. Krishna,et al. Sequestosome 1/p62 Is a Polyubiquitin Chain Binding Protein Involved in Ubiquitin Proteasome Degradation , 2004, Molecular and Cellular Biology.
[31] K. Nakashima,et al. Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible mechanisms and the role in Lewy body formation in Parkinson's disease , 2004, Brain Research.
[32] Jacques P. Brown,et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. , 2002, American journal of human genetics.
[33] B Miller,et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.
[34] E. Kuusisto,et al. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies , 2001, Neuroreport.
[35] R. Faber,et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.
[36] J. Strominger,et al. p62, a Phosphotyrosine-independent Ligand of the SH2 Domain of p56lck, Belongs to a New Class of Ubiquitin-binding Proteins* , 1996, The Journal of Biological Chemistry.
[37] S. Folstein,et al. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .
[38] S. Cappa,et al. Novel evidence of phenotypical variability in the hexanucleotide repeat expansion in chromosome 9. , 2013, Journal of Alzheimer's disease : JAD.
[39] Kurt Zatloukal,et al. p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. , 2002, The American journal of pathology.
[40] K. Davis,et al. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. , 1983, Psychopharmacology bulletin.